Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression

Journal of Urology

Volumn 174, Issue 6, 2005, Pages 2174-2177

  Osman, Iman ^b   Mikhail, Maryann ^b   Shuch, Brian ^b   Clute, Megan ^b   Cheli, Carol D ^b   Ghani, Farooq ^b   Thiel, Robert P ^b   Taneja, Samir S ^a  

^a NEW YORK UNIVERSITY   (United States)

^b NONE

Author keywords

Epidermal growth factor; Prostate; Prostatic neoplasms; Receptor; Serum

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CASTRATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

EID: 27744600091     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000181205.23233.65     Document Type: Article

References (20)

1. Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J. et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230: 1132, 1985
2. Ross, J. S., Fletcher, J. A., Bloom, K. J., Linette, G. P., Stec, J., Symmans, W. F. et al: Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics, 3: 379, 2004
3. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L. et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17: 2639, 1999
4. Vernimmen, D., Gueders, M., Pisvin, S., Delvenne, P. and Winkler, R.: Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer, 89: 899, 2003
5. Shi, Y., Brands, F. H., Chatterjee, S., Feng, A.-C., Groshen, S., Schewe, J. et al: Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol, 166: 1514, 2001
6. Osman, I., Scher, H. I., Drobnjak, M., Verbel, D., Morris, M., Agus, D. et al: HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res, 7: 2643, 2001
7. Morris, M. J., Reuter, V. E., Kelly, W. K., Slovin, S. F., Kenneson, K., Verbel, D. et al: HER-2 profiling and targeting in prostate carcinoma. Cancer, 94: 980, 2002
8. Scher, H. I. and Heller, G.: Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology, 55: 323, 2000
9. Scher, H. I., Eisenberger, M., D'Amico, A. V., Halabi, S., Small, E. J., Morris, M. et al: Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol, 22: 537, 2004
10. Payne, R. C., Allard, J. W., Anderson-Mauser, L., Humphreys, J. D., Tenney, D. Y. and Morris, D. L.: Automated assay for HER-2/neu in serum. Clin Chem, 46: 175, 2000
11. Nunes, R. A. and Harris, L. N.: The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer, 3: 125, 2002
12. Colomer, R., Montero, S., Lluch, A., Ojeda, B., Barnadas, A., Casado, A. et al: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res, 6: 2356, 2000
13. Lipton, A., Ali, S. M., Leitzel, K., Demers, L., Chinchilli, V., Engle, L. et al: Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol, 20: 1467, 2002
14. Meden, H., Marx, D., Schauer, A., Wuttke, W. and Kuhn, W.: Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer. Anticancer Res, 17: 757, 1997
15. Tsigris, C., Karayiannakis, A. J., Zbar, A., Syrigos, K. N., Baibas, N., Diamantis, T. et al: Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer. Cancer Lett, 184: 215, 2002
16. Ardizzoni, A., Cafferata, M. A., Paganuzzi, M., Filiberti, R., Marroni, P., Neri, M. et al: Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma. Cancer, 92: 1896, 2001
17. Polychronidis, A. C., Tsaroucha, A. K., Anagnostoulis, S. K., Efstathiou, E. E., Georgiadis, P. G. and Simopoulos, C. E.: Serum levels of c-erbb-2 correlate with advanced stage and liver metastasis in colorectal cancer. Folia Med (Plovdiv), 45: 12, 2003
18. Arai, Y., Yoshiki, T. and Yoshida, O.: c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate, 30: 195, 1997
19. Lara, P. N., Jr., Meyers, F. J., Gray, C. R., Edwards R. G., Gumerlock, P. H., Kauderer, C. et al: HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer, 94: 2584, 2002
20. Myers, R. B., Brown, D., Oelschlager, D. K., Waterbor, J. W., Marshall, M. E., Srivastava, S. et al: Elevated serum levels of p105(erbB-2) in patients with advanced-stage prostatic adenocarcinoma. Int J Cancer, 69: 398, 1996